7. Significant Biopharma Partnering Deals 2009 Pharma/Biotech Roche/PTC Therapeutics $ 1.9 billion Sanofi/Exelixis $ 1.0 billion Merck/Cardiome Pharma $ 700 million BMS/ZymoGenetics $ 1.1 billion Forest Labs/Nycomed $ 600 million Novartis/Portola Pharmaceuticals $ 575 million Wyeth/Catalyst Biosciences $ 500 million Biotech/Biotech Amgen/Cytokinetics $ 650 million Onyx Pharma/S*BIO Pte $ 550 million Celgene/GlobeImmune $ 500 million Biogen/Acorda Therapeutics $ 510 million Cephalon/Immunopharma $ 500 million Glaxo/Concert Pharmaceuticals $ 1.0 billion Glaxo/Chroma Therapeutics $ 1.0 billion Wyeth/Santaris Pharmaceuticals $ 847 million GSK/Idenix Pharmaceuticals $ 450 million Biovail/Acadia Pharmaceuticals $ 395 million Bayer/Ardea Biosciences $ 407 million Source: Burrill & Company
8. Venture Capital – Lifeblood of the Biotech Industry THE SPECTRUM OF PRIVATE (RISK) EQUITY CAPITAL Expansion Financing stage Seed Start-up Early stage Buy-outs, buy-ins Pre-seed Price Risk Idea, concept Proof-of-Concept Market estab-lished Clinical Studies Trade sale, IPO Venture capital M&A Incubators Business angels “ Triple F” (Family, friends & fools) Private equity
9. Biotech Financing Models “ Reasonable” Scenario (“In The Old Days”) Round Pre-money $ In Post-value Source Seed $1M $1M $2M Angels A $4M $6M $10M VCs B $20M $20M $40M VCs Mezz $80M $50M $130M VCs/Mezz IPO $250M $80M $340M Market & 2-3 Corporate Deals ($10-50+M)
11. Changing Face of Syndication Seed Series-A Series-B Series-C VC 1 VC 2 VC 3 VC 4 Exit (IPO/Trade sale) Years 1 2 3 4
12. Changing Business Models FIPCO (Fully Integrated Pharma Co.) Research Technology Manufacturing Clinical & Regulatory Sales & Distribution CSO CMO CROs Partnerships Academia, Scientific, Institutions R&D Preclinical Support Clinical Development Manufacturing Sales & Distribution Preclinical CRO VIPCO (Virtually Integrated Pharma Co.)
13.
14.
15.
16. Global Biotech Financing: Economic Stimulus (Partial List) Country Biotech Economic Stimulus Malaysia $21.5 B for R&D US China $4.81 B in 2009, $4.4B in 2010 for “11 technology projects” $129 B in healthcare infrastructure Norway $2.87 B for biotech industry Taiwan $1.83 B to biotech VC fund UK $1.5 B “fund of funds” Canada $200 M for science and technology RM182m in Second Stimulus Package
17.
18.
Editor's Notes
VCs typically invest post proof-of-concept In bad times VCs tend to fund later-stage deals as reduced time to exit + lower risk + lower valuations